Hims & Hers Health (NYSE:HIMS) Downgraded by Wall Street Zen to "Hold"

Hims & Hers Health (NYSE:HIMS - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday.

A number of other equities analysts have also commented on the stock. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Truist Financial set a $45.00 price target on Hims & Hers Health in a research note on Tuesday, June 24th. Piper Sandler reiterated a "neutral" rating and set a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $39.58.

Hims & Hers Health Stock Down 4.7%

Shares of HIMS stock traded down $2.36 on Friday, reaching $47.91. The company's stock had a trading volume of 18,925,676 shares, compared to its average volume of 23,898,503. Hims & Hers Health has a 12-month low of $13.47 and a 12-month high of $72.98. The stock's 50 day simple moving average is $53.68 and its 200-day simple moving average is $41.05. The company has a market capitalization of $10.72 billion, a P/E ratio of 69.44, a PEG ratio of 1.76 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. During the same quarter last year, the firm posted $0.05 EPS. The company's revenue was up 110.7% compared to the same quarter last year. Research analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,572 shares of the stock in a transaction on Monday, June 30th. The stock was sold at an average price of $50.50, for a total value of $129,886.00. Following the completion of the transaction, the insider owned 160,737 shares in the company, valued at approximately $8,117,218.50. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $46.67, for a total transaction of $540,485.27. Following the completion of the sale, the chief financial officer directly owned 58,078 shares in the company, valued at $2,710,500.26. This represents a 16.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 670,250 shares of company stock valued at $34,487,591 over the last ninety days. Insiders own 13.71% of the company's stock.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently made changes to their positions in HIMS. Vanguard Group Inc. grew its stake in shares of Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after acquiring an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after acquiring an additional 4,145,305 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after purchasing an additional 40,447 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.